RxDoctor Payments Data

Jacob Gardner, MD

Internal Medicine · Sarasota, FLNPI 1639674047

Payments from drug & device makers

$1,341in general payments, 2019–2025

Across 55 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$362
  • Lilly USA, LLC$297
  • AstraZeneca$202
  • Astellas Pharma US Inc$192
  • Exact Sciences$95
  • Pfizer$51
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$1,26294%
  • Education$665%
  • Entertainment$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,341 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$519,458
Medicare patients
1,034
Services billed
13,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$147,169
EliquisApixaban118$132,198
JardianceEmpagliflozin76$96,178
MounjaroTirzepatide61$78,187
XareltoRivaroxaban47$64,871
FarxigaDapagliflozin Propanediol31$38,299
MyrbetriqMirabegron30$32,748
WegovySemaglutide22$31,147
RybelsusSemaglutide11$25,411
Janumet XrSitagliptin Phos/Metformin Hcl15$11,962
Tresiba Flextouch U-200Insulin Degludec16$9,729
Omeprazole408$6,270
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$6,212
SynthroidLevothyroxine Sodium102$6,041
Atorvastatin Calcium672$5,908

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy, Rybelsus$362$203,727135 claims
PfizerEliquis, Paxlovid$51$136,363157 claims
Lilly USA, LLCMounjaro$297$78,18761 claims
AstraZenecaFarxiga$202$38,29931 claims
Astellas Pharma US IncMyrbetriq$192$32,74830 claims
MerckJanumet Xr$16$11,96215 claims
GSKBreo Ellipta$32$5,87411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →